Maria Gracia-Hernandez

Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

N. Lee, J. Pinilla-Ibarz, A. Kozikowski, 2019, Scientific Reports.

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

N. Lee, J. Pinilla-Ibarz, A. Kozikowski, 2019, Scientific Reports.

Targeting Macrophages as a Therapeutic Option in Coronavirus Disease 2019

E. Sotomayor, A. Villagra, Maria Gracia-Hernandez, 2020, Frontiers in Pharmacology.

Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers

A. Villagra, Maria Gracia-Hernandez, Zuleima Munoz, 2021, Cancers.

HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer

E. Sotomayor, A. Popratiloff, Katherine B. Chiappinelli, 2020, Cancer Research.

Targeting HDAC6 improves anti-CD47 immunotherapy

A. Yende, A. Villagra, S. Noonepalle, 2024, Journal of experimental & clinical cancer research : CR.

The advances in targeting CD47/SIRPα “do not eat me” axis and their ongoing challenges as an anticancer therapy

Maria Gracia-Hernandez, Manasa Suresh, Alejandro Villagra, 2024, Oncotarget.